Courtney Nuckols, NP
Family · Augusta, GANPI 1659963072
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $389, more than ten times the $32 reported in 2021.
Across 51 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$191
- Bayer$116
- Fresenius USA Marketing, Inc.$101
- Mallinckrodt Hospital Products Inc.$99
- Calliditas Therapeutics US Inc.$76
- Amgen$74
- plus $408 from 16 others
What the payments were for
- Food & beverage$1,04098%
- Education$252%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 7 | $191 |
| Bayer | 7 | $116 |
| Fresenius USA Marketing, Inc. | 6 | $101 |
| Mallinckrodt Hospital Products Inc. | 4 | $99 |
| Calliditas Therapeutics US Inc. | 3 | $76 |
| Amgen | 3 | $74 |
| GSK | 3 | $54 |
| AstraZeneca(2 entities) | 2 | $40 |
| Aurinia Pharma U.S., Inc. | 2 | $34 |
| KCI USA, Inc. | 2 | $32 |
| ANI Pharmaceuticals, Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Travere Therapeutics, Inc. | 1 | $25 |
| Akebia Therapeutics Inc | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Smith+Nephew | 1 | $19 |
| Ardelyx, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| Bioventus LLC | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$1,064 in reported general payments places this provider in the 65th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bumetanide | 37 | $2,389 |
| Potassium Chloride | 68 | $1,487 |
| Nifedipine ErNifedipine | 23 | $846 |
| Furosemide | 97 | $677 |
| Torsemide | 15 | $525 |
| Hydralazine Hcl | 27 | $475 |
| Spironolactone | 36 | $360 |
| Amlodipine Besylate | 63 | $290 |
| Losartan Potassium | 19 | $269 |
| Lisinopril | 43 | $231 |
| Hydrochlorothiazide | 23 | $133 |
Paid to pharmacies, not to this prescriber.
Other family in Augusta
- Stephanie JacobsonAugusta$24K
- Clovalyn Jeffrey-McgannAugusta$19K
- Victoria BurtAugusta$15K
- Gloria DowneyAugusta$14K
- Joni SmithAugusta$14K
- Lindsey RobertsAugusta$13K
- Allie McAllisterMarietta$299K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.